Herantis Pharma Plc's Financial Statements Release January 1 - December 31, 2017
Herantis Pharma Plc's Financial Statements Release January 1 - December 31, 2017 Clinical development progressed as planned Highlights in January-December 2017: · Phase 1 clinical study of Herantis Pharma ("Herantis") with Lymfactin® advanced to high dose level in March, and to its final patient cohort in June. The company announced in June having started planning a Phase 2 clinical study with Lymfactin®. · Sweden's medicines agency MPA approved Herantis' first-in-human clinical study with CDNF in Parkinson's disease (PD) in March. Finland's medicines agency Fimea approved the